AALL1521: INCB 18424-269 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia (ALL)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Acute Lymphoblastic Leukemia
  • Age: Between 2 - 21 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:

    1.  Patients must have newly diagnosed HR Ph-like B-ALL meeting any of the following:

          Patients ≥ 10 years at diagnosis

          WBC ≥ 50 X 10^3/µL

          CNS3 leukemia at diagnosis


    2.  Patients must have completed a 4-drug regimen Induction therapy


    3.  Patients should have eligible genetic alterations (please contact study PI for details)

You may not be eligible for this study if the following are true:

  • 1.  Receipt of any other cytotoxic chemotherapy before Induction therapy; prior treatment with a JAK inhibitor for any indication


    2.  Patients with BCR-ABL1-rearranged ALL


    3.  Patients with Trisomy 21; other malignancy in addition to ALL, or secondary ALL


    4.  Patients with chronic or current active infectious disease requiring systemic antibiotics, antifungal treatment, or antiviral treatment that is not well-controlled or resolving

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.